As TERT alterations are common in BRAF V600 mutant melanomas and plays an important role in controlling the apoptosis of cancer cells, combined therapies targeting both BRAF and TERT may potentially improvement the survival of these patients [108]. The gene discussed is BRAF; the disease is cancer.